A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Response</td><td align="center">Number (%) of patients</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Complete response</td><td align="center">11 (6)</td></tr><tr><td align="left">Partial response</td><td align="center">47 (24)</td></tr><tr><td align="left">Stable disease</td><td align="center">40 (20)</td></tr><tr><td align="left">Progressive disease</td><td align="center">35 (18)</td></tr><tr><td align="left">Unknown</td><td align="center">62 (32)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>The percentage is calculated out of 195, the total number of patients in the survey’s cohort.<br/></td></tr></table>

Best response at the end of oxaliplatin treatment.

Chemotherapy Research and Practice

tab2

Table 2

Table 2: A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer 

Table 2 | A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer 